ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Data as of , from SEC Form 4 filings.
See up to 3 months of ALNY. The 7-day demo opens the 1M and 3M ranges and puts ALNY on your watchlist.
Start 7-day demoLatest ALNY insider trades
About ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
- CAMBRIDGE, MA
- 2,500
- 2004
- XNAS
ALNY Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 1,758 | $399K |
| Grant or award | 1 | 107 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ALNY insider transactions (Form 4)
6077 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Olivier Brandicourt - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| Olivier Brandicourt - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
| Michael W. Bonney - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| Michael W. Bonney - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
| Margaret A. Hamburg - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| Margaret A. Hamburg - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
| Peter N. Kellogg - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| Peter N. Kellogg - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
| Amy W. Schulman - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| Amy W. Schulman - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
| Charles Elliott Sigal - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| Charles Elliott Sigal - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
| Carolyn R. Bertozzi - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| Carolyn R. Bertozzi - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
| David E. I. Pyott - Director | Grant or award | Common Stock | 775 | $0.00 | - | |
| David E. I. Pyott - Director | Grant or award | Stock Option (right to buy) | 1,558 | $0.00 | - | |
 Yvonne Greenstreet - Officer | Gift | Common Stock | 41,311 | $0.00 | - | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 121 | $247.48 | $30K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 186 | $248.99 | $46K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 426 | $250.08 | $107K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 778 | $251.68 | $196K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 100 | $252.94 | $25K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 140 | $254.37 | $36K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 1 | $255.80 | $256 | |
| Yvonne Greenstreet - Officer | Grant or award | Common Stock | 10,658 | $0.00 | - | |
| Yvonne Greenstreet - Officer | Open-market sale | Common Stock | 93 | $247.77 | $23K | |
| Yvonne Greenstreet - Officer | Open-market sale | Common Stock | 762 | $249.60 | $190K | |
| Yvonne Greenstreet - Officer | Open-market sale | Common Stock | 1,131 | $250.68 | $284K | |
| Yvonne Greenstreet - Officer | Open-market sale | Common Stock | 2,933 | $251.42 | $737K | |
| Yvonne Greenstreet - Officer | Open-market sale | Common Stock | 300 | $252.27 | $76K | |
| Pushkal Garg - Officer | Grant or award | Common Stock | 3,434 | $0.00 | - | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 30 | $247.77 | $7K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 246 | $249.60 | $61K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 364 | $250.68 | $91K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 945 | $251.42 | $238K | |
| Pushkal Garg - Officer | Open-market sale | Common Stock | 97 | $252.27 | $24K | |
| Jeffrey V. Poulton - Officer | Grant or award | Common Stock | 3,434 | $0.00 | - | |
| Jeffrey V. Poulton - Officer | Open-market sale | Common Stock | 30 | $247.77 | $7K | |
| Jeffrey V. Poulton - Officer | Open-market sale | Common Stock | 246 | $249.60 | $61K | |
| Jeffrey V. Poulton - Officer | Open-market sale | Common Stock | 364 | $250.68 | $91K | |
| Jeffrey V. Poulton - Officer | Open-market sale | Common Stock | 945 | $251.42 | $238K | |
| Jeffrey V. Poulton - Officer | Open-market sale | Common Stock | 97 | $252.27 | $24K | |
| Tolga Tanguler - Officer | Grant or award | Common Stock | 3,000 | $0.00 | - | |
| Tolga Tanguler - Officer | Open-market sale | Common Stock | 26 | $247.77 | $6K | |
| Tolga Tanguler - Officer | Open-market sale | Common Stock | 215 | $249.60 | $54K | |
| Tolga Tanguler - Officer | Open-market sale | Common Stock | 318 | $250.68 | $80K | |
| Tolga Tanguler - Officer | Open-market sale | Common Stock | 826 | $251.42 | $208K | |
| Tolga Tanguler - Officer | Open-market sale | Common Stock | 84 | $252.27 | $21K | |
 Kevin Joseph Fitzgerald - Officer | Grant or award | Common Stock | 3,000 | $0.00 | - | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 26 | $247.77 | $6K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 215 | $249.60 | $54K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 318 | $250.68 | $80K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 826 | $251.42 | $208K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 84 | $252.27 | $21K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 210 | $250.45 | $53K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 851 | $251.98 | $214K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 360 | $253.44 | $91K | |
| Kevin Joseph Fitzgerald - Officer | Open-market sale | Common Stock | 110 | $254.48 | $28K | |
| Pushkal Garg - Officer | Grant or award | Common Stock | 96 | $0.00 | - | |
| Robert W. Hesslein - Officer | Grant or award | Common Stock | 7,245 | $0.00 | - |
Recent ALNY Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| SUPRAN BRYAN | Officer | 1,758 | $399K | View on EDGAR | |
| - | - | - | - |
ALNY insider trading FAQ
What is the latest insider trade for ALNY?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had 2 insider filings in the last 90 days, with the most recent on 2026-10-06. The full record for ALNY runs to 77 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ALNY stock?
No insider purchases of ALNY were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling ALNY stock?
1 insider sale of ALNY was filed in the last 90 days, totaling $399K.
Where can I see ALNY SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ALNY Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Bryan Supran view on EDGAR
- - Yvonne Greenstreet view on EDGAR
- - David E. I. Pyott view on EDGAR
- - Benjamin Cravatt view on EDGAR
- - Charles Elliott Sigal view on EDGAR
- - Amy W. Schulman view on EDGAR
- - Colleen F. Reitan view on EDGAR
- - David E. I. Pyott view on EDGAR
- - Peter N. Kellogg view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ALNY's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ALNY with a 7-day demo
- ALNY on your watchlist
- Every ALNY Form 4 filing on record
- Up to 3 months of ALNY price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
